Prophylaxis for Hemophilia A and B with and without Inhibitors

Publication Date: April 27, 2022
Last Updated: November 3, 2022

Summary of Recommendations

  1. Prophylaxis should be initiated at an early age, ideally before age 3 years and prior to the second joint bleed; prophylaxis may be considered within the first six months of life to reduce occurrence of intracranial hemorrhage (see section on emicizumab prophylaxis for hemophilia A)
  2. Prophylaxis should be individualized (by dose and or frequency adjustment) and sufficient to prevent all bleeds at all times
  3. Options for prophylaxis include plasma-derived or recombinant standard half-life factor, extended half-life factor and non-factor replacement (Table 1).

Overview

Title

Prophylaxis for Hemophilia A and B with and without Inhibitors

Authoring Organization